Matrix metalloproteinase expression and outcome in patients with breast cancer: Analysis of a published database

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1566-1572

  McGowan, P M ^a,b   Duffy, Michael J ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Breast cancer and prognosis; Metalloproteinases

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 24; MESSENGER RNA; METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL RATE; SYSTEMIC THERAPY; TUMOR CLASSIFICATION; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MASTECTOMY, SEGMENTAL; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; REGISTRIES; RISK ASSESSMENT; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 50849134800     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn180     Document Type: Article

References (35)

1. Vu T, Werb Z. Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev 2000; 14: 2123-2133.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
3. Fingleton B. Matrix metalloproteinases: Roles in cancer and metastasis. Front Biosci 2006; 11: 479-491.
4. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992; 10: 145-155.
5. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007; 13: 333-346.
6. Watson SA, Tierney G. Matrix metalloproteinase inhibitors: A review. BioDrugs 1998; 9: 325-335.
7. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinases inhibitors and cancer: Trials and tribulations. Science 2002; 295: 2387-2392.
8. Martin MD, Matrisian LM. The other side of MMPs: Protective roles in tumor progression. Cancer Metastasis Rev 2007; 26: 717-724.
9. Lopez-Otin C, Matrisian LM. Emerging role of proteases in tumor suppression. Nat Rev Cancer 2007; 7: 800-808.
10. Overall CM, Kleifield O. Validation matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006, 6, 227-239.
11. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
12. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2002; 99: 12963-12968.
13. Sørlie T. Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. Eur J Cancer 2004; 40: 2667-2675.
14. Duffy MJ, Maguire TM, Hill A et al. Metalloproteinases: Role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000; 2: 252-257.
15. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005; 87: 287-297.
16. Vihinen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157-166.
17. Cheng S, Tada M, Hida Y et al. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma. J Surg Res 2007; 146: 104-109.
18. Poola I, DeWitty RL, Marshalleck JJ et al. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005; 11: 481-483.
19. Minn AJ, Kang Y, Serganova I et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115: 44-55.
20. Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
21. Gupta GP, Nguyen DX, Chiang AC et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007; 446: 765-770.
22. Li HC, Cao DC, Liu Y et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004; 88: 75-85.
23. Rahko E, Jukkola A, Melkko J et al. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy. Anticancer Res 2004; 24: 4247-4253.
24. Scorilas A, Karameris A, Amogiannaki N et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: A potential favourable indicator in node-negative patients. Br J Cancer 2001; 84: 1488-1496.
25. Pellikainen JM, Ropponen KM, Kataja VV et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004; 10: 7621-7628.
26. Yang W, Arii S, Gorrin-Rivas MJ et al. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer 2001; 91: 1277-1283.
27. Hofmann HS, Hansen G, Richter G et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res 2005; 11: 1086-1092.
28. Kerkelä E, Ala-aho R, Klemi P et al. Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol 2002; 198: 258-269.
29. Houghton AM, Grisolano JL, Baumann ML et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res 2006; 66: 6149-6155.
30. Acuff HB, Sinnamon M, Fingleton B et al. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res 2006; 66: 7968-7975.
31. Wolf K, Wu YI, Liu Y et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007: 9893-9904.
32. Têtu B, Brisson J, Wang CS et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006; 8: R28.
33. Abraham R, Schafer J, Rothe M et al. Identification of MMP15 as an antiapoptotic factor in cancer cells. J Biol Chem 2005; 280: 34123-34132.
34. Chenard MP, O'Siorain L, Shering S et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996; 69: 448-451.
35. Paik S, Shak S, Tang G et al. A multi-gene assay to predict recurrence of tamoxifen-treated node-negative breast cancer. N Engl J Med 2005; 347: 2817-2826.